The current average rate of successful clinical translation from animal models & cell culture studies to clinical trials is very low(8%). These animal models fail to portray the array of complicated reactions occurring within humans & the cell cultures don’t give an accurate representation of the 3D tissue structure, thereby failing to mimic the in vivo microenvironment.
Well the solution for this does not need some breakthrough innovation, but a complex coordination of making multiple exponential technologies to work together – 3D printing (bioprinting), biology (tissue culture assay), nanotechnology & machine learning.
3D printing is used to generate 3d tissue cultures, which mimic the in vivo protein expression of tissue. Advantages of such 3D cell cultures are proximity of other cells on all sides, behavior akin to in vivo conditions, as well as more accurate representation of cytoarchitecture. The testing data generated can be compared to historical behavior and an analytical model can predict the drug success rate at the lab level, thus saving countless hours and millions of dollars of animal testing.
Such a platform would eventually replace animal testing for drug development, thereby reducing the time & cost at which new drugs and therapies come to market and positively impact lives of billions. Such an in-vivo-mimic testing platform (Organ-On-Chip) would not only provide an test bed for pharma, but also can be used in the field of stem cell therapies research, cosmetics dev & personalized medicine.
Next Big Innovation Labs has developed of assay based 3d bioprinted tissue research platform which is being used for cancer research & drug testing applications. Presently the technology is being validated for breast cancer research & drug applications with industry partner Mazumdar Shaw Center for Translational Research (MSCTR). Next Big Innovation Labs has also received INR 50,00,000 Karnataka government Idea2Poc grant for the developing of its bioprinting research platform. The company has also got Startup India recognition & is presently incubated at Bangalore Bioinnovation Center.